Clifton E Barry

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint In vivo phenotypic dominance in mouse mixed infections with Mycobacterium tuberculosis clinical isolates
    Amy K Barczak
    Tuberculosis Research Section, Laboratory of Immunogenetics, National Institute for Allergy and Infectious Diseases, National Institutes of Health NIH, Rockville, and Howard Hughes Medical Institute NIH Research Scholars Program, Bethesda, Maryland, USA
    J Infect Dis 192:600-6. 2005
  2. ncbi request reprint Drug sensitivity and environmental adaptation of mycobacterial cell wall components
    C E Barry
    Tuberculosis Research Unit, National Institutes for Allergy and Infectious Diseases, Rocky Mountain Laboratories, Hamilton, MT 59840 2999, USA
    Trends Microbiol 4:275-81. 1996
  3. ncbi request reprint New horizons in the treatment of tuberculosis
    C E Barry
    Laboratory of Intracellular Parasites, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, MT 59840 2999, USA
    Biochem Pharmacol 54:1165-72. 1997
  4. ncbi request reprint Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs
    C E Barry
    Tuberculosis Research Section, Laboratory of Host Defenses, NIAID, NIH, Rockville, MD 20852, USA
    Biochem Pharmacol 59:221-31. 2000
  5. ncbi request reprint Interpreting cell wall 'virulence factors' of Mycobacterium tuberculosis
    C E Barry
    Tuberculosis Research Section, LHD, National Institute of Allergy and Infectious Disease, NIH, 12441 Parklawn Drive, Rm 239, Rockville, MD 20852 1742, USA
    Trends Microbiol 9:237-41. 2001
  6. ncbi request reprint Preclinical candidates and targets for tuberculosis therapy
    C E Barry
    Tuberculosis Research Secton, LHD, NIAID, NIH, Rockville, MD 20852, USA
    Curr Opin Investig Drugs 2:198-201. 2001
  7. ncbi request reprint Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis
    Clifton E Barry
    Tuberculosis Research Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Curr Pharm Des 10:3239-62. 2004
  8. pmc Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles
    Pilho Kim
    Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Med Chem 52:1317-28. 2009
  9. pmc Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships
    Pilho Kim
    Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Med Chem 52:1329-44. 2009
  10. pmc PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release
    Ramandeep Singh
    Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA
    Science 322:1392-5. 2008

Detail Information

Publications68

  1. ncbi request reprint In vivo phenotypic dominance in mouse mixed infections with Mycobacterium tuberculosis clinical isolates
    Amy K Barczak
    Tuberculosis Research Section, Laboratory of Immunogenetics, National Institute for Allergy and Infectious Diseases, National Institutes of Health NIH, Rockville, and Howard Hughes Medical Institute NIH Research Scholars Program, Bethesda, Maryland, USA
    J Infect Dis 192:600-6. 2005
    ..However, phagocyte preactivation reduced and equalized the growth rate of both strains. These results suggest that HN878 exerts a dominant immunosuppressive effect limited to the granuloma in which it is contained...
  2. ncbi request reprint Drug sensitivity and environmental adaptation of mycobacterial cell wall components
    C E Barry
    Tuberculosis Research Unit, National Institutes for Allergy and Infectious Diseases, Rocky Mountain Laboratories, Hamilton, MT 59840 2999, USA
    Trends Microbiol 4:275-81. 1996
    ..The complex regulatory and biosynthetic pathways involved in cell wall biosynthesis and construction offer useful chemotherapeutic targets against mycobacteria...
  3. ncbi request reprint New horizons in the treatment of tuberculosis
    C E Barry
    Laboratory of Intracellular Parasites, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, MT 59840 2999, USA
    Biochem Pharmacol 54:1165-72. 1997
    ....
  4. ncbi request reprint Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs
    C E Barry
    Tuberculosis Research Section, Laboratory of Host Defenses, NIAID, NIH, Rockville, MD 20852, USA
    Biochem Pharmacol 59:221-31. 2000
    ..Understanding the mechanisms involved in activation of current antimycobacterial therapeutics also may facilitate the development of alternative activation strategies or of analogs that require no such processes...
  5. ncbi request reprint Interpreting cell wall 'virulence factors' of Mycobacterium tuberculosis
    C E Barry
    Tuberculosis Research Section, LHD, National Institute of Allergy and Infectious Disease, NIH, 12441 Parklawn Drive, Rm 239, Rockville, MD 20852 1742, USA
    Trends Microbiol 9:237-41. 2001
    ..Affected processes include the surface exposure or secretion of the many lipid, glycolipid and proteinaceous molecules that can interact directly with components of the host cell...
  6. ncbi request reprint Preclinical candidates and targets for tuberculosis therapy
    C E Barry
    Tuberculosis Research Secton, LHD, NIAID, NIH, Rockville, MD 20852, USA
    Curr Opin Investig Drugs 2:198-201. 2001
    ..New targets and lead compounds with activity against the mycobacterial cell wall and non-replicating bacilli are the subject of current discovery programs...
  7. ncbi request reprint Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis
    Clifton E Barry
    Tuberculosis Research Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Curr Pharm Des 10:3239-62. 2004
    ....
  8. pmc Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles
    Pilho Kim
    Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Med Chem 52:1317-28. 2009
    ..Aerobic activity appears to be correlated with efficiency as a substrate for Ddn, suggesting a means of structure-based optimization of improved nitroimidazoles...
  9. pmc Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships
    Pilho Kim
    Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Med Chem 52:1329-44. 2009
    ..A simple four-feature QSAR model was derived to rationalize MIC results in this series of bicyclic nitroimidazoles...
  10. pmc PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release
    Ramandeep Singh
    Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA
    Science 322:1392-5. 2008
    ..Furthermore, NO scavengers protected the bacilli from the lethal effects of the drug. Thus, these compounds may act as intracellular NO donors and could augment a killing mechanism intrinsic to the innate immune system...
  11. pmc Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance
    Pilar Domenech
    Tuberculosis Research Section, Laboratory of Immunogenetics, 12441 Parklawn Drive, Rockville, MD 20852, USA
    Infect Immun 73:3492-501. 2005
    ....
  12. pmc Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824
    Xiaojin Li
    Tuberculosis Research Section, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA
    Bioorg Med Chem Lett 18:2256-62. 2008
    ..Additionally, these results suggest that the nitroreductase that initially recognizes PA-824 is somewhat insensitive to substitutions at the 7-position...
  13. doi request reprint The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
    Clifton E Barry
    Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Microbiol 7:845-55. 2009
    ..We then show how this model can be used to develop a rational programme to discover effective drugs for the eradication of M. tuberculosis infection...
  14. pmc Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [¹⁸F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography
    Laura E Via
    Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute for Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA
    Antimicrob Agents Chemother 56:4391-402. 2012
    ..The results from this study suggest that rabbits may be a useful surrogate species for evaluating novel chemotherapies and understanding changes in both PET and CT scans in human clinical trials...
  15. pmc Fumarate reductase activity maintains an energized membrane in anaerobic Mycobacterium tuberculosis
    Shinya Watanabe
    Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 7:e1002287. 2011
    ..This fermentative process may offer unique targets for the treatment of latent tuberculosis...
  16. pmc SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis
    Kapil Tahlan
    Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute for Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA
    Antimicrob Agents Chemother 56:1797-809. 2012
    ..Our results suggest that MmpL3 is the target of SQ109 and that MmpL3 is a transporter of mycobacterial TMM...
  17. pmc Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis
    Laura E Via
    Tuberculosis Research Section, Laboratory of Clinical Infectious Disease, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA
    J Clin Microbiol 48:402-11. 2010
    ....
  18. ncbi request reprint Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates
    Richard E Lee
    Tuberculosis Research Section, NIAID, National Institutes of Health, Rockville, Maryland 20850, USA
    J Comb Chem 5:172-87. 2003
    ..N-Geranyl-N'-(2-adamantyl)ethane-1,2-diamine (109), the most active of these diamines, displayed a 14-35-fold improvement in activity in vitro against Mycobacterium tuberculosis, as compared to EMB...
  19. ncbi request reprint The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action
    Helena I M Boshoff
    Tuberculosis Research Section, NIAID, National Institutes of Health, Rockville, Maryland 20852, USA
    J Biol Chem 279:40174-84. 2004
    ....
  20. pmc Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis
    Matthew W Carroll
    Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Antimicrob Agents Chemother 57:3903-9. 2013
    ..Newer nitroimidazoles with both aerobic and anaerobic activity, now in clinical trials, may increase the sterilizing potency of future treatment regimens. ..
  21. pmc Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus)
    Laura E Via
    Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute for Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA
    Infect Immun 81:2909-19. 2013
    ..tuberculosis strain clades. ..
  22. pmc Meropenem inhibits D,D-carboxypeptidase activity in Mycobacterium tuberculosis
    Pradeep Kumar
    Tuberculosis Research Section, National Institute of Allergy and Infectious Disease, NIH, Bethesda, MD 20892, USA
    Mol Microbiol 86:367-81. 2012
    ....
  23. pmc Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli
    Helena I M Boshoff
    Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, NIAID, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 283:19329-41. 2008
    ..These studies demonstrate the plasticity of the organism in maintaining NAD levels and establish that the two enzymes of the universal pathway are attractive chemotherapeutic targets for active as well as latent tuberculosis...
  24. pmc BacA, an ABC transporter involved in maintenance of chronic murine infections with Mycobacterium tuberculosis
    Pilar Domenech
    Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Disease, 33 North Drive, Bethesda, Maryland 20892, USA
    J Bacteriol 191:477-85. 2009
    ..These results suggest a striking conservation of function for BacA-related proteins in transport of a critical molecule that determines the outcome of the host-pathogen interaction...
  25. pmc Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis
    Ujjini H Manjunatha
    Tuberculosis Research Section, National Institute of Allergy and Infectious Diseases, 12441 Parklawn Drive, Twinbrook II, Rockville, MD 20852, USA
    Proc Natl Acad Sci U S A 103:431-6. 2006
    ..These results suggest that the sensitivity of Mtb to PA-824 and related compounds is mediated by a protein that is highly specific for subtle structural variations in these bicyclic nitroimidazoles...
  26. pmc Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates
    Laura E Via
    Tuberculosis Research Section, Laboratory of Clinical Infectious Disease, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20852, USA
    Infect Immun 76:2333-40. 2008
    ..Thus, three independent lines of evidence support the hypothesis that hypoxic microenvironments are an important feature of some lesions in these animal models of tuberculosis...
  27. ncbi request reprint A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response
    Michael B Reed
    Tuberculosis Research Section, NIAID, National Institutes of Health, 12441 Parklawn Drive, Rockville, Maryland 20852, USA
    Nature 431:84-7. 2004
    ..Furthermore, the overproduction of PGL by M. tuberculosis or the addition of purified PGL to monocyte-derived macrophages was found to inhibit the release of these pro-inflammatory mediators in a dose-dependent manner...
  28. ncbi request reprint The role of MmpL8 in sulfatide biogenesis and virulence of Mycobacterium tuberculosis
    Pilar Domenech
    Tuberculosis Research Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 12441 Parklawn Drive, Rockville, MD 20852, USA
    J Biol Chem 279:21257-65. 2004
    ....
  29. pmc Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli
    Pilho Kim
    Tuberculosis Research Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20852, USA
    J Med Chem 49:159-71. 2006
    ..These results suggest a strict requirement for a conjugated, planar side chain inserting within the condensing enzyme active site...
  30. pmc Mycobacterium leprae is naturally resistant to PA-824
    Ujjini H Manjunatha
    Tuberculosis Research Section, National Institute of Allergy and Infectious Diseases, Rockville, MD 20852, USA
    Antimicrob Agents Chemother 50:3350-4. 2006
    ..leprae in all three models, consistent with the lack of the nitroimidazo-oxazine-specific nitroreductase, encoded by Rv3547 in the M. leprae genome, which is essential for activation of this molecule...
  31. pmc The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice
    John L Dahl
    Tuberculosis Research Section, National Institute of Allergy and Infectious Disease, 12441 Parklawn Drive, Rockville, MD 20852, USA
    Proc Natl Acad Sci U S A 100:10026-31. 2003
    ..Thus, RelMtb is critical for the successful establishment of persistent infection in mice by altering the expression of antigenic and enzymatic factors that may contribute to successful latent infection...
  32. pmc Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo
    Kathleen England
    Tuberculosis Research Section, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA
    Antimicrob Agents Chemother 56:3384-7. 2012
    ..Our results show that meropenem has activity in two in vivo systems, but stability and pharmacokinetics of long-term administration will offer significant challenges to clinical evaluation...
  33. ncbi request reprint Targeting the formation of the cell wall core of M. tuberculosis
    Clifton E Barry
    Tuberculosis Research Section, Laboratory of Clinical Infectious Disease, NIAID, NIH, 33 North Drive Bldg 33, Room 2W20D Bethesda, MD 20892, USA
    Infect Disord Drug Targets 7:182-202. 2007
    ..Selected enzymes will then be discussed in more detail. It is thus hoped this chapter will aid in the selection of targets for new drugs to combat tuberculosis...
  34. pmc Functional role of methylation of G518 of the 16S rRNA 530 loop by GidB in Mycobacterium tuberculosis
    Sharon Y Wong
    Tuberculosis Research Section, Laboratory of Clinical Infectious Disease, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA
    Antimicrob Agents Chemother 57:6311-8. 2013
    ..These results provide a mechanistic explanation for the low-level, SM-resistant phenotype observed in M. tuberculosis strains that contain a gidB mutation. ..
  35. pmc Rv2607 from Mycobacterium tuberculosis is a pyridoxine 5'-phosphate oxidase with unusual substrate specificity
    Ellene H Mashalidis
    National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 6:e27643. 2011
    ..The k(cat) and K(M) for this reaction were 0.01 s(-1) and 360 µM, respectively. Unlike many PNPOx enzymes, Rv2607 does not recognize PMP as a substrate...
  36. pmc Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles
    Meera Gurumurthy
    Novartis Institute for Tropical Diseases, Singapore, Singapore
    FEBS J 279:113-25. 2012
    ..The results presented provide insight into the biochemical mechanism of reduction and elucidate structural features important for understanding substrate binding...
  37. pmc Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis
    Sharon Y Wong
    Tuberculosis Research Section, Laboratory of Clinical Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 55:2515-22. 2011
    ..This report provides the first microbiological evidence for the contribution of gidB in streptomycin resistance and examines the clinical implications of mutations in the gidB gene...
  38. ncbi request reprint DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis
    Helena I M Boshoff
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook II, 12441 Parklawn Drive, Rockville, MD 20852, USA
    Cell 113:183-93. 2003
    ..These results may indicate a potential new target for therapeutic intervention...
  39. ncbi request reprint Lessons from seven decades of antituberculosis drug discovery
    Clifton E Barry
    Tuberculosis Research Section, LCID, NIAID, NIH, Bethesda, MD, USA
    Curr Top Med Chem 11:1216-25. 2011
    ..Looking forward we must accelerate the integration of these past lessons with the impressive advances that have been made in the basic understanding of the biology of this disease...
  40. ncbi request reprint Quantification of small molecule organic acids from Mycobacterium tuberculosis culture supernatant using ion exclusion liquid chromatography/mass spectrometry
    Michael B Goodwin
    Tuberculosis Research Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, Rockville, Maryland 20852, USA
    Rapid Commun Mass Spectrom 20:3345-50. 2006
    ..Supernatant samples were spiked with stable-isotope-labeled internal standards, and the organic acids were quantified by isotope ratiometry...
  41. ncbi request reprint Tuberculosis - metabolism and respiration in the absence of growth
    Helena I M Boshoff
    Tuberculosis Research Section, LIG NIAID NIH, Twinbrook II, Room 239, 12441 Parklawn Drive, Rockville, Maryland 20852, USA
    Nat Rev Microbiol 3:70-80. 2005
    ..A complete picture of bacterial metabolism must balance reducing equivalents while maintaining an energized membrane and basic cellular processes...
  42. pmc The chemical biology of new drugs in the development for tuberculosis
    Clifton E Barry
    Tuberculosis Research Section, Laboratory of Clinical Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD 20892, United States
    Curr Opin Chem Biol 14:456-66. 2010
    ..These agents have novel mechanisms of action that are not targeted by the standard drugs used presently to treat susceptible strains...
  43. pmc Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I
    Helena I Boshoff
    Tuberculosis Research Section, National Institute of Allergy and Infectious Diseases, Rockville, Maryland 20852, USA
    J Bacteriol 184:2167-72. 2002
    ..Moreover, we demonstrate that pyrazinoic acid does not inhibit purified mycobacterial FAS-I, suggesting that this enzyme is not the immediate target of pyrazinamide...
  44. pmc Proteasomal protein degradation in Mycobacteria is dependent upon a prokaryotic ubiquitin-like protein
    Kristin E Burns
    Tuberculosis Research Section, NIAID, NIH, Bethesda, MD 20892, USA
    J Biol Chem 284:3069-75. 2009
    ..These data therefore establish that, despite differences in both sequence and target linkage, Pup plays an analogous role to ubiquitin in targeting proteins to the proteasome for degradation...
  45. pmc Genetic diversity of Mycobacterium tuberculosis isolates from a tertiary care tuberculosis hospital in South Korea
    Isdore Chola Shamputa
    Tuberculosis Research Section, Laboratory of Clinical Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Microbiol 48:387-94. 2010
    ..tuberculosis Beijing strains. Within the study limits, our results also suggest that the problem of drug-resistant TB in the Republic of Korea may be largely due to acquired resistance as opposed to transmission...
  46. pmc Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action
    Katherine A Sacksteder
    Sequella, Inc, Rockville, MD, USA
    Future Microbiol 7:823-37. 2012
    ..We describe herein the identification, development and characterization of SQ109 as a promising new antitubercular drug...
  47. doi request reprint Multidrug-resistant and extensively drug-resistant tuberculosis: the National Institute of Allergy and Infectious Diseases Research agenda and recommendations for priority research
    Anthony S Fauci
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9000 Rockville Pike, Bldg 31, Rm 7A05, Bethesda, MD 20892, USA
    J Infect Dis 197:1493-8. 2008
  48. ncbi request reprint Rationally designed nucleoside antibiotics that inhibit siderophore biosynthesis of Mycobacterium tuberculosis
    Ravindranadh V Somu
    Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Med Chem 49:31-4. 2006
    ..19 microM) that disrupts siderophore biosynthesis was identified. The activity is due to inhibition of the adenylate-forming enzyme MbtA which is involved in biosynthesis of the mycobactins...
  49. pmc Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity
    Gilla Kaplan
    Laboratory of Mycobacterial Immunity and Pathogenesis, Newark, New Jersey, USA
    Infect Immun 71:7099-108. 2003
    ....
  50. ncbi request reprint Prospects for new antitubercular drugs
    Ken Duncan
    GlaxoSmithKline, Gunnels Wood Road, Stevenage, SG1 2NY, UK
    Curr Opin Microbiol 7:460-5. 2004
    ..Few such novel pre-clinical drug candidates exist and therefore considerable effort is being exerted to employ new tools to identify drug targets essential for survival of Mycobacterium tuberculosis...
  51. pmc Antitubercular nucleosides that inhibit siderophore biosynthesis: SAR of the glycosyl domain
    Ravindranadh V Somu
    Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, MN 55455, USA
    J Med Chem 49:7623-35. 2006
    ..Additionally, we report improved conditions for the expression of MbtA and biochemical analysis, demonstrating that MbtA follows a random sequential enzyme mechanism for the adenylation half-reaction...
  52. pmc The W-Beijing lineage of Mycobacterium tuberculosis overproduces triglycerides and has the DosR dormancy regulon constitutively upregulated
    Michael B Reed
    The Research Institute of the McGill University Health Centre, Montreal General Hospital, 1650 Cedar Ave, Montreal, Quebec, Canada H3G 1A4
    J Bacteriol 189:2583-9. 2007
    ....
  53. ncbi request reprint Elemental analysis of Mycobacterium avium-, Mycobacterium tuberculosis-, and Mycobacterium smegmatis-containing phagosomes indicates pathogen-induced microenvironments within the host cell's endosomal system
    Dirk Wagner
    Kuzell Institute for Arthritis and Infectious Diseases, San Francisco, CA 94115, USA
    J Immunol 174:1491-500. 2005
    ..tuberculosis vacuoles exhibited retarded acquisition of iron compared with phagosomes with wild-type M. tuberculosis. This is a unique approach to define the environmental conditions within the pathogen-containing compartment...
  54. pmc Differential monocyte activation underlies strain-specific Mycobacterium tuberculosis pathogenesis
    Claudia Manca
    Laboratory of Mycobacterial Immunity and Pathogenesis, Public Health Research Institute, International Center for Public Health, 225 Warren St, Newark, NJ 07103 3535, USA
    Infect Immun 72:5511-4. 2004
    ..The differential cytokine-chemokine response was mediated by extracted lipids, suggesting that these molecules regulate host responses to infection...
  55. ncbi request reprint A community-based tuberculosis program in Cambodia
    Sok Thim
    JAMA 292:566-8. 2004
  56. pmc Inhibition of Mycobacterium tuberculosis AhpD, an element of the peroxiredoxin defense against oxidative stress
    Aleksey Koshkin
    University of California, Genentech Hall N572D, 600 16th Street, San Francisco, CA 94143 2280, USA
    Antimicrob Agents Chemother 48:2424-30. 2004
    ..This finding, and the low solubility of the inhibitor, explains its inability to suppress the growth of INH-resistant M. tuberculosis in infected mouse lungs...
  57. ncbi request reprint Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis
    Benjawan Phetsuksiri
    Department of Microbiology, Pathology, and Immunology, Colorado State University, Fort Collins, Colorado 80523 1682, USA
    J Biol Chem 278:53123-30. 2003
    ..These results validate membrane-bound Delta9-desaturase, DesA3, as a new therapeutic target, and the thioureas as anti-tuberculosis drugs worthy of further development...
  58. ncbi request reprint Top down characterization of secreted proteins from Mycobacterium tuberculosis by electron capture dissociation mass spectrometry
    Ying Ge
    Department of Chemistry and Chemical Biology, Baker Laboratory, Cornell University, Ithaca, NY 14853 1301, USA
    J Am Soc Mass Spectrom 14:253-61. 2003
    ..Although in eubacteria the latter is relatively rare, a 9 kDa protein showed 7 hexose attachments and two 20 kDa proteins each had 20 attachments. For MS/MS, electron capture dissociation was especially effective...
  59. ncbi request reprint Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli
    Liana Tsenova
    Laboratory of Mycobacterial Immunity and Pathogenesis, The Public Health Research Institute, Newark, New Jersey 07103, USA
    J Infect Dis 192:98-106. 2005
    ....
  60. pmc Inhibition of siderophore biosynthesis in Mycobacterium tuberculosis with nucleoside bisubstrate analogues: structure-activity relationships of the nucleobase domain of 5'-O-[N-(salicyl)sulfamoyl]adenosine
    João Neres
    Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Med Chem 51:5349-70. 2008
    ....
  61. ncbi request reprint Getting the iron out
    Clifton E Barry
    Nat Chem Biol 1:127-8. 2005
  62. pmc Design, synthesis, and biological evaluation of beta-ketosulfonamide adenylation inhibitors as potential antitubercular agents
    Jagadeshwar Vannada
    Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Org Lett 8:4707-10. 2006
    ..Herein, we report efforts to refine this inhibitor scaffold by replacing the labile acylsulfamate linkage (highlighted) with the more chemically robust beta-ketosulfonamide linkage of 3 and 4...
  63. ncbi request reprint Expression, production and release of the Eis protein by Mycobacterium tuberculosis during infection of macrophages and its effect on cytokine secretion
    Linoj P Samuel
    Department of Microbiology and Immunology, University of Arizona, Tucson, AZ 85724, USA
    Microbiology 153:529-40. 2007
    ..These results suggest that Eis is a mycobacterial effector that is released into the host cell to modulate inflammatory responses, possibly via transcriptional or post-translational means...
  64. pmc 5'-O-[(N-acyl)sulfamoyl]adenosines as antitubercular agents that inhibit MbtA: an adenylation enzyme required for siderophore biosynthesis of the mycobactins
    Chunhua Qiao
    Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, MN 55455, USA
    J Med Chem 50:6080-94. 2007
    ....
  65. doi request reprint Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital
    Christie Y Jeon
    Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
    Clin Infect Dis 46:42-9. 2008
    ..Extensively drug-resistant (XDR) tuberculosis (TB) is a major public health threat in South Korea...
  66. pmc Evaluation of the diagnostic utility of a whole-blood interferon-gamma assay for determining the risk of exposure to Mycobacterium tuberculosis in Bacille Calmette-Guerin (BCG)-vaccinated individuals
    Seok Yong Eum
    International Tuberculosis Research Center, Division of Immunopathology and Cell Immunology, Masan, Republic of Korea
    Diagn Microbiol Infect Dis 61:181-6. 2008
    ....
  67. pmc Confronting the scientific obstacles to global control of tuberculosis
    Douglas B Young
    Division of Medicine, Faculty of Medicine, Imperial College London, London, United Kingdom
    J Clin Invest 118:1255-65. 2008
    ....
  68. pmc Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins
    Ida Rosenkrands
    Department of TB Immunology, Statens Serum Institut, Copenhagen, Denmark
    J Bacteriol 184:3485-91. 2002
    ..These results extend our understanding of the hypoxic response in M. tuberculosis and potentially provide important insights into the physiology of the latent bacilli...